Amylyx Pharmaceuticals, Inc. AMLX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -63.3%-1.7pp | -61.6%-5.1pp | -56.5%+30.9pp | -87.4%-4.2pp | -83.2%+17.6pp | |
| Return on invested capital | -165.3%+11.0pp | -176.3%-46.4pp | -129.9%-0.8pp | -129.1%+24.2pp | -153.3%+23.1pp | |
| Liquidity | ||||||
| Current ratio | 17.9×+3.6× | 14.3×+0.6× | 13.7×+5.0× | 8.7×-3.3× | 12.1×+5.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $2.47-23.5% | $3.23-9.3% | $3.56+88.9% | $1.88-19.9% | $2.35-2.8% | |
| Valuation | ||||||
| Market capitalization | $1.54B+15.8% | $1.33B-8.5% | $1.45B+154% | $571.39M+82.2% | $313.65M+21.0% | |
| Price / book | 5.6×+1.3× | 4.3×0.0× | 4.4×+1.0× | 3.4×+1.8× | 1.6×0.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amylyx Pharmaceuticals, Inc.'s profit margins?
- Amylyx Pharmaceuticals, Inc. (AMLX) runs a 100.0% gross margin and a -47349.8% operating margin, with a -45096.2% net margin.
- Where do Amylyx Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Amylyx Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.